Anticoagulation in Device-Detected Atrial Fibrillation—Uncertainty and Heterogeneity in Value
-
By
-
Hanxuan Yu
-
Jinyi Zhu
-
June 8, 2026
-
Objective:
To evaluate the clinical and economic implications of anticoagulation strategies for patients with device-detected atrial fibrillation (AF).
Key Findings:
- Clarify that the findings are derived from pooled results of the ARTESiA and NOAH-AFNET 6 trials.
Interpretation:
Remove unsupported conclusions about routine anticoagulation.
Limitations:
- Rephrase to indicate that limitations are based on the study's findings.
Conclusion:
Revise to reflect only the statements made in the source without recommendations.
